(Information sent by the signatory company)
- Suvoda announces 30% growth in 2023 driven by strong customer adoption of new Suvoda platform and products
Company maintained industry-leading quality metrics throughout growth surge
PHILADELPHIA, Jan. 8, 2024 /PRNewswire/ -- Suvoda LLC, a global clinical trial technology company specializing in complex studies in therapeutic areas such as oncology, central nervous system (CNS), and rare diseases, surpassed 1,400 clinical trials in 2023 and increased sales by 30% year over year, indicating broad acceptance of the company's new unified clinical trials platform that focuses on mission-critical and urgent moments in the patient journey in trials clinical.
Suvoda made significant investments in its technology platform and offerings in 2023, including the launch of a low-code or no-code application design layer. Organically built to deliver the next generation of Suvoda solutions, the Suvoda platform was designed to handle complexity with ease, reduce overall risk during trials, and address the real challenges faced by clinical trial professionals. Built as the foundation for Suvoda IRT, eCOA, and eConsent, the platform minimizes friction in the user experience, reduces and simplifies integrations, and strengthens data governance, enabling studies to be deployed more efficiently for sponsors and users. of the site can spend less time on technology and more time focusing on their patients.
In another milestone, Suvoda's electronic clinical outcomes assessments (eCOA) solution became widely available, completed third-party usability testing, and was certified by RWS Life Sciences as highly usable and effective for the patient population. Seamlessly integrated with Suvoda IRT and eConsent, Suvoda eCOA is rapidly setting a new standard with eCOA studies that launch on time, a licensing and localization process that is easy to navigate, and increased patient adherence, resulting in results in more and better data.
"We spend a lot of time listening to trial sponsors, CROs, sites and patients to understand their challenges, and we use that feedback to create practical solutions designed to streamline processes, simplify workflows and improve your overall experience "especially in 'urgent moments' in a patient's clinical trial process," said Jagath Wanninayake, CEO of Suvoda. "We continue to distinguish ourselves by staying true to our approach of delivering excellence and being a true partner and trusted advisor to our clients. Our team is made up of some of the most innovative and experienced scientific and technological minds, both outside the life sciences, and our customers are seeing the positive impact our people, processes and products have on their trials.”
Despite the company's rapid growth in 2023, Suvoda has maintained outstanding quality metrics, including an average of less than one functional and one cosmetic UAT defect per study, and a resolution time for high-priority support tickets of around 25 minutes. The company also continues to boast 100% on-time deliveries across the board.
Suvoda is a global clinical trial technology company specializing in complex life support studies in therapeutic areas such as oncology, central nervous system (CNS), and rare diseases. Founded in 2013 by eClinical technology experts, Suvoda enables clinical trial professionals to manage the most urgent moments in the most urgent trials through advanced software solutions delivered on a single platform. Headquartered outside of Philadelphia, Suvoda also has offices in Portland, Oregon, Barcelona, Spain, Bucharest and Iasi, Romania, and Tokyo, Japan. The company's Net Promoter Score (NPS) consistently exceeds the technology industry average, helping the company to be selected by trial sponsors and CROs to support more than 1,400 trials in 85 countries. For more information, visit suvoda.com. Follow Suvoda on LinkedIn and X.
For more information, contact:
Deb Massa email@example.com
Logo - https://mma.prnewswire.com/media/1759317...
View original content: https://www.prnewswire.com/news-releases/suvoda-anuncia-un-crecimiento-del-30-en-2023-impulsado-por-la-fuerte-adopcion-de-la-plataforma-suvoda-302025164.html